Azenta Life Sciences, formerly GENEWIZ OncoGxOne™ Discovery cancer panels provide comprehensive genomic analysis for cancer research, biomarker discovery, and patient stratification. Designed and developed with the most recent research data available, these assays provide thorough assessments on cancer genes of interest.
*Development of assays for other cancer types with flexibility to add or subtract genes from premade panels available upon request.
||Azenta Pan-Cancer Panel||GENEWIZ OncoGxOneTM
Discovery Cancer Panels
Amplicon Cancer Panel
|Sequencing Platform||Illumina MiSeq or HiSeq||Illumina MiSeq or HiSeq||Illumina MiSeq|
|Cancer Types Assayed||Single gene panel assay for multiple cancer types
||19 distinct gene panels, each assays a specific cancer (organ) type||Single gene panel assays multiple cancer types|
|Genes Covered||634||≈150 - 400||48|
|Genomic Variation Detection||
|Target Regions||≈ 2 Mb, consisting of exons and targeted promoter regions||≈ 2 - 5.4 Mb, consisting of all exons, UTRs, and relevant intron regions||≈35 Kb, consisting of mutational hot spots|
|Average Depth||>100x*||> 100x*||> 100x*|
|Target Enrichment||Twist Targeted Enrichment||Agilent SureSelect Targeted Enrichment||Illumina Targeted Amplicon Sequencing|
|DNA Input||> 100 ng||> 100 ng||> 250 ng|
Azenta accepts formalin-fixed, paraffin-embedded (FFPE) thin sections (slides), purified genomic DNA, or fresh, frozen samples for Cancer Panel projects. For detailed sample submission requirements please visit our Sample Submission Guidelines page.
All customers receive their raw data as FASTQ files. Mutation discovery and customizable data analysis packages are available by request.
Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.
Azenta is a certified service provider for Illumina NGS platforms and the PacBio Sequel. Please visit our NGS Platforms page for more information.